Nonprofits Launch AI-Enabled Marketplace for Shelved Cell and Gene Therapies
The American Society of Gene & Cell Therapy (ASCGT) and Orphan Therapeutics Accelerator (OTXL) have jointly launched CGTxchange, an artificial intelligence-enabled marketplace designed to revive shelved cell and gene therapy (CGT) assets. The platform aims to connect academics, investors, biotechs, and non-profit developers to reinvigorate development programs for assets previously discarded due to funding constraints rather than safety or efficacy issues. OTXL COO Beth White describes the platform as a two-sided marketplace similar to Zillow, offering a simplified scoring system for preclinical data, clinical efficacy, safety, and regulatory paths to help potential partners evaluate opportunities. The initiative addresses a growing trend where economic factors have forced major pharmaceutical companies, such as Novo Nordisk and Takeda, to pause or abandon CGT programs. By facilitating licensing and alternative financing models, including non-profit approaches, CGTxchange seeks to provide a new lease on life for promising but stalled therapies, particularly those targeting rare diseases, thereby improving accessibility and commercial viability in the sector.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection